IN2012DN02752A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN02752A IN2012DN02752A IN2752DEN2012A IN2012DN02752A IN 2012DN02752 A IN2012DN02752 A IN 2012DN02752A IN 2752DEN2012 A IN2752DEN2012 A IN 2752DEN2012A IN 2012DN02752 A IN2012DN02752 A IN 2012DN02752A
- Authority
- IN
- India
- Prior art keywords
- dii4
- vegf
- binding molecules
- binding component
- bispecific binding
- Prior art date
Links
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09172137 | 2009-10-02 | ||
| EP10175316 | 2010-09-03 | ||
| PCT/EP2010/064695 WO2011039370A1 (en) | 2009-10-02 | 2010-10-01 | Bispecific binding molecules for anti-angiogenesis therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN02752A true IN2012DN02752A (OSRAM) | 2015-09-18 |
Family
ID=43431796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2752DEN2012 IN2012DN02752A (OSRAM) | 2009-10-02 | 2010-10-01 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20110172398A1 (OSRAM) |
| EP (1) | EP2483314A1 (OSRAM) |
| JP (2) | JP5833009B2 (OSRAM) |
| KR (1) | KR20120101375A (OSRAM) |
| CN (2) | CN102639566B (OSRAM) |
| AP (1) | AP2012006188A0 (OSRAM) |
| AR (1) | AR078515A1 (OSRAM) |
| AU (1) | AU2010302589A1 (OSRAM) |
| BR (1) | BR112012007239A2 (OSRAM) |
| CA (1) | CA2775422A1 (OSRAM) |
| CL (1) | CL2012000826A1 (OSRAM) |
| EA (1) | EA201200548A1 (OSRAM) |
| EC (1) | ECSP12011835A (OSRAM) |
| IL (1) | IL218542A0 (OSRAM) |
| IN (1) | IN2012DN02752A (OSRAM) |
| MA (1) | MA33607B1 (OSRAM) |
| MX (1) | MX2012003897A (OSRAM) |
| NZ (2) | NZ598956A (OSRAM) |
| PE (1) | PE20121024A1 (OSRAM) |
| PH (1) | PH12012500525A1 (OSRAM) |
| TN (1) | TN2012000145A1 (OSRAM) |
| TW (1) | TW201124533A (OSRAM) |
| UY (1) | UY32920A (OSRAM) |
| WO (1) | WO2011039370A1 (OSRAM) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA018260B1 (ru) * | 2006-09-29 | 2013-06-28 | Онкомед Фармасьютикалз, Инк. | Антитела к дельта-подобному лиганду 4 человека и их применение |
| JP5646457B2 (ja) | 2008-04-29 | 2014-12-24 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリン及びその使用 |
| NZ589434A (en) | 2008-06-03 | 2012-11-30 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| JP5723769B2 (ja) | 2008-06-03 | 2015-05-27 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリン及びその使用 |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| SG172789A1 (en) | 2009-02-11 | 2011-08-29 | Novozymes Biopharma Dk As | Albumin variants and conjugates |
| EP2424567B1 (en) | 2009-04-27 | 2018-11-21 | OncoMed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| EP2470568A2 (en) | 2009-08-29 | 2012-07-04 | Abbott Laboratories | Therapeutic dll4 binding proteins |
| UY32920A (es) * | 2009-10-02 | 2011-04-29 | Boehringer Ingelheim Int | Moleculas de unión biespecíficas para la terapia anti-angiogénesis |
| PL2488204T3 (pl) | 2009-10-16 | 2016-10-31 | Kombinacja terapeutyczna i zastosowanie przeciwciał antagonistycznych względem dll4 i środków antyhipertensyjnych | |
| RU2607374C2 (ru) | 2009-10-30 | 2017-01-10 | Новозаймс Байофарма Дк А/С | Варианты альбумина |
| EP3072904A1 (en) | 2010-03-02 | 2016-09-28 | Abbvie Inc. | Therapeutic dll4 binding proteins |
| ES2949159T3 (es) | 2010-05-06 | 2023-09-26 | Novartis Ag | Composiciones y métodos de uso para anticuerpos terapéuticos de proteína 6 relacionada con lipoproteínas de baja densidad (LRP6) |
| BR112012028326A2 (pt) | 2010-05-06 | 2017-03-21 | Novartis Ag | anticorpo multivalente isolado, anticorpos biparatópicos isolados, ácido nucleico, vetor, composição farmacêutica, método de obtenção dos referidos anticorpos, bem como uso do dos mesmos |
| JP2013537522A (ja) | 2010-07-19 | 2013-10-03 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 抗癌治療への応答可能性の増大した患者を同定する方法 |
| KR20130126576A (ko) | 2010-07-19 | 2013-11-20 | 에프. 호프만-라 로슈 아게 | 항암요법에 반응할 가능성이 증가된 환자를 확인하는 방법 |
| SG188190A1 (en) | 2010-08-03 | 2013-04-30 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| JP2013539364A (ja) | 2010-08-26 | 2013-10-24 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリンおよびその使用 |
| US20120225081A1 (en) * | 2010-09-03 | 2012-09-06 | Boehringer Ingelheim International Gmbh | Vegf-binding molecules |
| US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
| US20130323265A1 (en) * | 2010-11-15 | 2013-12-05 | Oncomed Pharmaceuticals, Inc. | Methods for treating cancer with dll4 antagonists |
| US20130078247A1 (en) | 2011-04-01 | 2013-03-28 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to dii4 and ang2 |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| AU2015268749B2 (en) * | 2011-09-23 | 2017-05-25 | Oncomed Pharmaceuticals, Inc. | VEGF/DLL4 binding agents and uses thereof |
| DK3485903T5 (da) | 2011-09-23 | 2024-09-02 | Mereo Biopharma 5 Inc | Vegf/dll4-bindende midler og anvendelser deraf |
| JP2015502741A (ja) | 2011-11-04 | 2015-01-29 | ノバルティス アーゲー | 低比重リポタンパク質関連タンパク質６（ｌｒｐ６）−半減期延長構築物 |
| US20140315817A1 (en) | 2011-11-18 | 2014-10-23 | Eleven Biotherapeutics, Inc. | Variant serum albumin with improved half-life and other properties |
| US9120870B2 (en) | 2011-12-30 | 2015-09-01 | Abbvie Inc. | Dual specific binding proteins directed against IL-13 and IL-17 |
| MX2014010278A (es) | 2012-03-16 | 2015-03-05 | Novozymes Biopharma Dk As | Variantes de albumina. |
| MX361337B (es) | 2012-07-13 | 2018-12-04 | Roche Glycart Ag | Anticuerpos biespecificos anti-factor de crecimiento endotelial vascular humano (vegf) / anti-angiopoyetina-2 humana (ang-2) y su uso en el tratamiento de enfermedades vasculares oculares. |
| EA201500371A1 (ru) * | 2012-09-28 | 2015-08-31 | Бёрингер Ингельхайм Интернациональ Гмбх | ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ, СОДЕРЖАЩИЕ ДВОЙНЫЕ АНГИПОЭТИН-2/Dll4 СВЯЗЫВАЮЩИЕ АГЕНТЫ И АНТИ-VEGF АГЕНТЫ |
| KR20150060687A (ko) * | 2012-09-28 | 2015-06-03 | 베링거 인겔하임 인터내셔날 게엠베하 | 이중 안지오포이에틴-2/Dll4 결합제 및 항-VEGF-R 제제를 포함하는 약제학적 조합물 |
| WO2014062659A2 (en) * | 2012-10-15 | 2014-04-24 | Oncomed Pharmaceuticals, Inc. | Methods of treating ocular diseases |
| AU2013337811A1 (en) * | 2012-10-31 | 2015-05-14 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a DLL4 antagonist |
| MY171664A (en) * | 2012-11-01 | 2019-10-22 | Abbvie Inc | Anti-dll4/vegf dual variable domain immunoglobulins and uses thereof |
| EP3466973A1 (en) * | 2012-11-01 | 2019-04-10 | AbbVie Inc. | Stable dual variable domain immunoglobulin protein formulations |
| CN105452290A (zh) | 2012-11-08 | 2016-03-30 | 诺维信生物制药丹麦公司 | 白蛋白变体 |
| AU2014227732A1 (en) | 2013-03-15 | 2015-09-17 | Abbvie Inc. | Dual specific binding proteins directed against IL-1 beta and IL-17 |
| RU2648154C2 (ru) * | 2013-07-09 | 2018-03-22 | Аблбио | Новые белки, специфично связывающиеся с двумя мишенями -dll4 и vegf-, и их применение |
| WO2015123359A1 (en) * | 2014-02-11 | 2015-08-20 | Albany Medical College | Multi-functional mucosal vaccine platform |
| BR112016023011A2 (pt) * | 2014-04-04 | 2017-10-17 | Oncomed Pharm Inc | tratamento de câncer gástrico |
| US20170267784A1 (en) | 2014-10-23 | 2017-09-21 | Singh Molecular Medicine, Llc | Single domain antibodies directed against intracellular antigens |
| JP6827415B2 (ja) | 2014-10-31 | 2021-02-10 | メレオ バイオファーマ ５ インコーポレイテッド | 疾患の処置のための併用療法 |
| WO2016094881A2 (en) | 2014-12-11 | 2016-06-16 | Abbvie Inc. | Lrp-8 binding proteins |
| WO2016192613A1 (zh) * | 2015-06-01 | 2016-12-08 | 中山大学 | 具有融合至常规Fab片段的单域抗原结合片段的二价抗体 |
| TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白 |
| CA2989966C (en) | 2015-08-20 | 2024-04-30 | Albumedix A/S | Albumin variants and conjugates |
| ES2968074T3 (es) | 2015-09-23 | 2024-05-07 | Mereo Biopharma 5 Inc | Anticuerpo bi-específico anti-VEGF/DLL4 para su uso en el tratamiento del cáncer de ovario resistente al platino |
| TWI746473B (zh) * | 2015-11-02 | 2021-11-21 | 美商辛分子醫藥有限公司 | 針對細胞內抗原之單域抗體 |
| RU2018123709A (ru) | 2015-12-04 | 2020-01-09 | Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния | Новые антитела для лечения онкологических заболеваний |
| WO2017131230A1 (ja) * | 2016-01-29 | 2017-08-03 | 国立大学法人京都大学 | 血小板産生促進剤及びそれを用いた血小板の製造方法 |
| MX2019008827A (es) * | 2017-01-30 | 2019-09-26 | Alexion Pharma Inc | Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo. |
| EP3749690A1 (en) * | 2018-02-05 | 2020-12-16 | Stichting VU | Inverse agonistic anti-us28 antibodies |
| CN111995686B (zh) * | 2019-05-27 | 2022-06-14 | 兰州大学 | 一种具有抗血管生成活性的药物及其制备方法 |
| TWI844709B (zh) * | 2019-07-31 | 2024-06-11 | 美商美國禮來大藥廠 | 鬆弛素(relaxin)類似物及其使用方法 |
| CN110452297B (zh) * | 2019-09-03 | 2020-04-14 | 上海洛启生物医药技术有限公司 | 抗vegf单域抗体及其应用 |
| TW202221027A (zh) * | 2020-09-17 | 2022-06-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 特異性結合ｖｅｇｆ和ａｎｇ－２的雙特異性抗原結合分子 |
| CN112535738B (zh) * | 2020-12-04 | 2022-09-09 | 中国科学技术大学 | 奥沙利铂偶联物及其制备方法和应用 |
| MX2023009392A (es) * | 2021-02-10 | 2023-11-09 | Shanghai Jemincare Pharmaceuticals Co Ltd | Anticuerpo anti-vegf y uso del mismo. |
| CN115724968B (zh) * | 2021-08-27 | 2023-08-08 | 三优生物医药(上海)有限公司 | Vegf结合分子及其用途 |
| EP4436996A4 (en) * | 2021-11-24 | 2025-10-08 | Linno Pharmaceuticals Inc | VEGF-BINDING PROTEIN AND ITS USE |
| CN116063469B (zh) * | 2022-08-29 | 2023-09-22 | 中山大学 | 一种寨卡病毒中和性纳米抗体及其制备方法与应用 |
| EP4582447A1 (en) * | 2022-09-14 | 2025-07-09 | Quaerite Biopharm Research (Beijing) Co., Ltd. | Anti-vegfa antibody or antigen-binding fragment thereof and use thereof |
| WO2024106394A1 (ja) | 2022-11-14 | 2024-05-23 | 株式会社Ｃоｇｎａｎо | 抗体及び抗体を生産する方法 |
| CN117686722B (zh) * | 2023-12-20 | 2024-08-09 | 内蒙古元牛繁育科技有限公司 | 一种s100a4纳米抗体及其应用 |
| CN117860786B (zh) * | 2024-03-12 | 2024-06-04 | 北京贝来药业有限公司 | 基因修饰间充质干细胞在多种疾病中的制药用途和诊断用途 |
| CN120025456B (zh) * | 2024-03-13 | 2025-11-07 | 寻济生物科技（北京）有限公司 | 一种抗vegfa融合构建体及其制备方法和应用 |
| WO2025212751A1 (en) * | 2024-04-02 | 2025-10-09 | Therini Bio, Inc. | Multi-specific antigen-binding proteins which bind human fibrin yc or fibrinogen yc domain and vascular endothelial growth factor and methods of use |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69330523D1 (de) | 1992-08-21 | 2001-09-06 | Vrije Universiteit Brussel Bru | Immunoglobuline ohne leichte ketten |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
| EP2275557A1 (en) | 2000-04-12 | 2011-01-19 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| EP2316951A1 (en) | 2001-01-17 | 2011-05-04 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| WO2003002609A2 (en) | 2001-06-28 | 2003-01-09 | Domantis Limited | Dual-specific ligand and its use |
| CA2484556A1 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US20060228355A1 (en) | 2003-11-07 | 2006-10-12 | Toon Laeremans | Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor |
| AU2003286002B2 (en) | 2002-11-08 | 2011-06-16 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| JP2006519763A (ja) | 2002-11-08 | 2006-08-31 | アブリンクス エン．ヴェー． | 治療用ポリペプチドの投与法およびそのためのポリペプチド |
| KR101025143B1 (ko) | 2002-12-31 | 2011-04-01 | 넥타르 테라퓨틱스 | 가수분해상으로 안정한 말레이미드－종결 중합체 |
| EP2390270A1 (en) * | 2003-01-10 | 2011-11-30 | Ablynx N.V. | Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation |
| DE602004017726D1 (de) | 2003-06-30 | 2008-12-24 | Domantis Ltd | Pegylierte Single-domain-antikörper (dAb) |
| WO2005040219A1 (en) * | 2003-10-28 | 2005-05-06 | Novo Nordisk A/S | Laminin-5 gamma2-binding peptides, related compositions, and use thereof |
| US20050284249A1 (en) | 2004-06-29 | 2005-12-29 | Arnone David F | Worm type gear mover assembly |
| JP5113523B2 (ja) | 2004-10-13 | 2013-01-09 | アブリンクス ナームローゼ フェンノートシャップ | アミロイド−βに対するナノ抗体及びアルツハイマー病のような神経変性疾患の治療のためのナノ抗体ＴＭを含むポリペプチド |
| US8048418B2 (en) * | 2004-10-29 | 2011-11-01 | Regeneron Pharmaceuticals, Inc. | Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists |
| EP2949668B1 (en) | 2005-05-18 | 2019-08-14 | Ablynx N.V. | Improved nanobodies tm against tumor necrosis factor-alpha |
| BRPI0609797B8 (pt) * | 2005-05-20 | 2021-05-25 | Ablynx Nv | nanocorpos melhorados para o tratamento de desordens mediadas por agregação |
| US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| NZ568739A (en) | 2005-12-16 | 2010-09-30 | Regeneron Pharma | Therapeutic methods for inhibiting tumor growth with delta-like ligand 4 antagonists |
| CA2654000A1 (en) * | 2006-06-06 | 2008-05-22 | Genentech, Inc. | Anti-dll4 antibodies and methods using same |
| CA2654304A1 (en) | 2006-06-06 | 2007-12-13 | Genentech, Inc. | Compositions and methods for modulating vascular development |
| ZA200809100B (en) * | 2006-06-06 | 2009-12-30 | Genentech Inc | Anti-DLL4 antibodies and methods using same |
| CN101500605B (zh) * | 2006-08-07 | 2014-04-30 | 瑞泽恩制药公司 | Dll4拮抗剂在治疗局部缺血性损伤中的用途 |
| AU2007285695B2 (en) | 2006-08-18 | 2012-05-24 | Ablynx N.V. | Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling |
| WO2008070513A1 (en) * | 2006-12-01 | 2008-06-12 | Alcon Research, Ltd. | Modulation of polysialylated neural adhesion molecules (psa-ncam) as a regulator of ocular disease |
| NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| US20110118185A9 (en) * | 2007-02-21 | 2011-05-19 | Ablynx N.V. | Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization |
| GB0709333D0 (en) * | 2007-05-15 | 2007-06-20 | Smart Targeting Ltd | Binding protein |
| WO2009095489A2 (en) | 2008-02-01 | 2009-08-06 | Ablynx N.V. | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
| WO2009109635A2 (en) | 2008-03-05 | 2009-09-11 | Ablynx Nv | Novel antigen binding dimer-complexes, methods of making and uses thereof |
| CA2720763A1 (en) * | 2008-04-07 | 2009-10-15 | Ablynx Nv | Amino acid sequences directed against the notch pathways and uses thereof |
| JP5646457B2 (ja) * | 2008-04-29 | 2014-12-24 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリン及びその使用 |
| US8268314B2 (en) * | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| EP2424567B1 (en) * | 2009-04-27 | 2018-11-21 | OncoMed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| UY32920A (es) * | 2009-10-02 | 2011-04-29 | Boehringer Ingelheim Int | Moleculas de unión biespecíficas para la terapia anti-angiogénesis |
-
2010
- 2010-09-30 UY UY0001032920A patent/UY32920A/es not_active Application Discontinuation
- 2010-09-30 US US12/894,989 patent/US20110172398A1/en not_active Abandoned
- 2010-10-01 PH PH1/2012/500525A patent/PH12012500525A1/en unknown
- 2010-10-01 WO PCT/EP2010/064695 patent/WO2011039370A1/en not_active Ceased
- 2010-10-01 NZ NZ598956A patent/NZ598956A/en not_active IP Right Cessation
- 2010-10-01 EP EP10768428A patent/EP2483314A1/en not_active Withdrawn
- 2010-10-01 KR KR1020127011329A patent/KR20120101375A/ko not_active Ceased
- 2010-10-01 PE PE2012000422A patent/PE20121024A1/es not_active Application Discontinuation
- 2010-10-01 JP JP2012531451A patent/JP5833009B2/ja not_active Expired - Fee Related
- 2010-10-01 AR ARP100103596A patent/AR078515A1/es unknown
- 2010-10-01 AP AP2012006188A patent/AP2012006188A0/xx unknown
- 2010-10-01 CN CN201080054891.9A patent/CN102639566B/zh not_active Expired - Fee Related
- 2010-10-01 NZ NZ626302A patent/NZ626302A/en not_active IP Right Cessation
- 2010-10-01 BR BR112012007239A patent/BR112012007239A2/pt not_active IP Right Cessation
- 2010-10-01 TW TW099133632A patent/TW201124533A/zh unknown
- 2010-10-01 IN IN2752DEN2012 patent/IN2012DN02752A/en unknown
- 2010-10-01 MX MX2012003897A patent/MX2012003897A/es not_active Application Discontinuation
- 2010-10-01 AU AU2010302589A patent/AU2010302589A1/en not_active Abandoned
- 2010-10-01 EA EA201200548A patent/EA201200548A1/ru unknown
- 2010-10-01 CA CA2775422A patent/CA2775422A1/en not_active Abandoned
- 2010-10-01 CN CN201510363066.1A patent/CN105037542A/zh active Pending
-
2012
- 2012-03-08 IL IL218542A patent/IL218542A0/en unknown
- 2012-03-26 MA MA34720A patent/MA33607B1/fr unknown
- 2012-03-29 TN TNP2012000145A patent/TN2012000145A1/en unknown
- 2012-04-02 CL CL2012000826A patent/CL2012000826A1/es unknown
- 2012-04-26 EC ECSP12011835 patent/ECSP12011835A/es unknown
-
2013
- 2013-03-22 US US13/848,826 patent/US20140120095A1/en not_active Abandoned
-
2015
- 2015-10-28 JP JP2015211551A patent/JP2016026207A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20110172398A1 (en) | 2011-07-14 |
| NZ598956A (en) | 2014-07-25 |
| MX2012003897A (es) | 2012-05-08 |
| CN105037542A (zh) | 2015-11-11 |
| JP2013506411A (ja) | 2013-02-28 |
| AP2012006188A0 (en) | 2012-04-30 |
| IL218542A0 (en) | 2012-05-31 |
| WO2011039370A1 (en) | 2011-04-07 |
| UY32920A (es) | 2011-04-29 |
| KR20120101375A (ko) | 2012-09-13 |
| MA33607B1 (fr) | 2012-09-01 |
| CL2012000826A1 (es) | 2012-10-19 |
| AR078515A1 (es) | 2011-11-16 |
| BR112012007239A2 (pt) | 2019-09-24 |
| TW201124533A (en) | 2011-07-16 |
| PE20121024A1 (es) | 2012-08-10 |
| PH12012500525A1 (en) | 2012-11-26 |
| NZ626302A (en) | 2015-09-25 |
| ECSP12011835A (es) | 2012-06-29 |
| CN102639566B (zh) | 2015-07-22 |
| EP2483314A1 (en) | 2012-08-08 |
| EA201200548A1 (ru) | 2012-12-28 |
| CA2775422A1 (en) | 2011-04-07 |
| JP2016026207A (ja) | 2016-02-12 |
| AU2010302589A1 (en) | 2012-04-19 |
| CN102639566A (zh) | 2012-08-15 |
| TN2012000145A1 (en) | 2013-09-19 |
| JP5833009B2 (ja) | 2015-12-16 |
| US20140120095A1 (en) | 2014-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN02752A (OSRAM) | ||
| PH12013500410B1 (en) | Vegf-binding molecules | |
| TN2013000390A1 (en) | Bispecific binding molecules binding to vegf and ang2 | |
| TN2012000144A1 (en) | Dll4-binding molecules | |
| PH12014502179A1 (en) | Ang2-binding molecules | |
| WO2014004549A3 (en) | Anti-mesothelin binding proteins | |
| NZ623607A (en) | Anti-gcc antibody molecules and related compositions and methods | |
| MX345226B (es) | Formulaciones de moleculas de union a antigeno de dominio sencillo. | |
| MX2018003292A (es) | Polipéptidos de unión a cd3. | |
| WO2015108998A8 (en) | Cartilage targeting agents and their use | |
| WO2013173761A3 (en) | St2 antigen binding proteins | |
| WO2013119966A3 (en) | Single-chain antibodies and other heteromultimers | |
| TN2013000389A1 (en) | BISPECIFIC BINDING MOLECULES BINDING TO Dll4 AND Ang2 | |
| NZ761636A (en) | Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods | |
| MX2016008478A (es) | Nuevo anticuerpo anti adam17 y su uso en el tratamiento del cancer. |